5 / 10
Page 29
International Journal of Applied Science - Research and Review
ISSN 2394-9988
E u r o p e a n C o n f e r e n c e o n
Agriculture, Horticulture
& Epigenetics
F e b r u a r y 2 5 - 2 6 , 2 0 1 9
P a r i s , F r a n c e
Agriculture & Epigenetics 2019
E
pigenetic reprogramming including altered transcription factor binding and
altered patterns of chromatin and DNA modifications are now accepted
as the hallmark of aggressive cancers. I will show that global changes in
chromatin structure and chromatin accessibility in prostate tumour tissue can
define castrate-resistant prostate cancer and present mechanistic insights
of the effect of androgen receptor deregulation on the chromatin. Such
effects translate into epigenetics reprogramming of tumor cells mediated
by bromodomain containing proteins. Finally, I will present BROMO-10, a
gene signature with high prognostic value and predictive of response to
bromodomain inhibitors, which are now in clinical trials also for advanced
prostate cancer. Bromodomain containing proteins can be used also as
disease biomarkers, and I will show that BRD4 in particular can identify DNA
stretches enriched in low p-value GWAS-significant disease/tissue-specific
susceptibility loci including breast and prostate cancer.
Biography
Alfonso Urbanucci graduated from the University of Perugia, in
Italy, and got his PhD in Cancer Genetics and Molecular Biology
of Cancer in Finland at the University of Tampere in 2012.
His personal research interest is on the transcriptional and
chromatin drivers underpinning prostate cancer progression
with the androgen receptor as a focal point. He published
a series of papers regarding the molecular effects of the
deregulation of the androgen receptor on the chromatin and
transcription, and how these drive prostate cancer progression.
He then moved to Oslo at the Centre for Molecular Medicine
Norway (EMBL partnership), and subsequently at the Oslo
University Hospital, where he investigated the mechanism of
action of bromodomain inhibitors and derived novel prognostic
tools for patient stratification. He is currently Researcher at the
Norwegian Radium Hospital.
alfonsourbanucci@gmail.comChromatin deregulation in prostate cancer
Alfonso Urbanucci
1, 2
1
Institute of Cancer Research and Radium Hospital, Norway
2
Centre for Molecular Medicine Norway-University of Oslo, Norway
Alfonso Urbanucci, Int J Appl Sci Res Rev 2019, Volume: 6
DOI: 10.21767/2394-9988-C1-008